hit counter
Adamas Pharmaceuticals, Inc. (ADMS) Stock News Sentiment & Price - Sentifly
ADMS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Adamas Pharmaceuticals, Inc. (ADMS)

USA
Drugs - Generic
NASDAQ
ADMS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ADMS Latest news
The Motley Fool
Positive
Why Supernus' Acquisition of Adamas Is a Smart Move
2021-10-21 07:03

Adamas looks like a good fit for Supernus.

PRNewsWire
Neutral
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations
2021-10-18 17:46

NEW YORK , Oct. 18, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS)  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) in connection with the proposed acquisition of the company by Supernus Pharmaceuticals, Inc.  Under the terms of the agreement, ADMS shareholders will receive $8.10 per share in cash, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of ADMS's lead product, GOCOVRI, for each share of ADMS stock that they hold.

PRNewsWire
Neutral
SHAREHOLDER ALERT: WeissLaw LLP Investigates Adamas Pharmaceuticals, Inc.
2021-10-11 19:53

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) in connection with the proposed acquisition of the Company by Supernus Pharmaceuticals, Inc. ("Supernus") (NASDAQ: SUPN), via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $8.10 per share in cash payable at closing, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of the Company's lead product, GOCOVRI, for each share of Adamas common stock that they hold.

Newsfile Corp
Neutral
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Adamas Pharmaceuticals, Inc. with Supernus Pharmaceuticals, Inc.
2021-10-11 15:30

New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) ("Adamas" or the "Company") stock prior to October 11, 2021. To view an enhanced version of this graphic, please visit:

PRNewsWire
Neutral
Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus
2021-10-11 13:37

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus. Click here to learn how to join the action: https://www.ademilaw.com/case/adamas-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

InvestorPlace
Positive
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
2021-10-11 12:02

ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News appeared first on InvestorPlace.

Business Wire
Neutral
Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS
2021-10-11 11:39

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash is fair to Adamas shareholders. Halper Sadeh encourages Adamas shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halpe

Benzinga
Positive
Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
2021-10-11 08:53

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal consideration includes $8.10 per share in cash ($400 million) and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash.

Pulse2
Positive
ADMS Stock: Why It Substantially Increased Today
2021-10-11 08:38

The stock price of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) increased by over 70% pre-market today. This is why it happened.

Business Wire
Neutral
Adamas Announces New Employment Inducement Grants
2021-10-08 16:15

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of

Loading more news...